苯巴那酯的用法用量？

Usage

Cenobamate is an oral small molecule neurotherapeutic compound developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy.

Patients should take the medicine with water when taking the medicine. They can take it with or without eating, and avoid chewing.

Phenobarate needs to be taken orally once a day as monotherapy and adjuvant therapy, and the recommended dose should not be exceeded to avoid serious adverse reactions to the drug.

For adults with partial-onset epilepsy, the recommended initial dose is 12.5 mg once daily during weeks 1 and 2. Then gradually increase to 25 mg once a day in weeks 3 and 4. 50 mg once daily in weeks 5 and 6, 100 mg once daily in weeks 7 and 8, and 150 mg once daily in weeks 9 and 10. The maintenance dose for weeks 11 and thereafter is 200 mg once daily.

The maximum dosage of phenobarnate is above 200 mg. Patients can increase the dosage according to clinical response and tolerance under the guidance of a doctor, increasing by 50 mg every two weeks until 400 mg, once a day.

Medication for patients with hepatic insufficiency

For patients with mild to moderate hepatic impairment (liver function assessment 5-9 points), the dose should be adjusted to 200 mg once daily. Phenobarate is not recommended for patients with severe hepatic impairment.

Discontinue medication

Patients are not allowed to stop taking the drug without permission, or reduce or increase the dose without permission, to avoid sudden discontinuation of the medication that may cause serious adverse reactions to the medication, or even cause unstoppable epileptic seizures. If the patient needs to stop taking the drug, the dose should be gradually reduced over at least two weeks as directed by the doctor.

adverse reactions

During medication, patients may experience increased eosinophils, shortened QT interval on electrocardiogram, systemic symptoms (fever, rash, lymphadenopathy, etc.), neurological adverse reactions (drowsiness, fatigue, weakness, etc.), multi-organ hypersensitivity reactions, suicidal behavior tendencies, etc.

Recommended related articles: